ALAN LISTHAUS, MD
Ophthalmology Physician · ALLENTOWN, PA
Individual Active NPI 1205881992
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,715 | 33,804 | $6,592,281 | $3,535,397 | $2,746,962 |
| 2023 | 1,747 | 21,206 | $6,315,321 | $3,326,334 | $2,578,265 |
| 2022 | 1,759 | 13,056 | $5,622,175 | $2,981,285 | $2,308,379 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 21,120 | $35 | $28 |
| 92134 | Imaging of retina | 3,213 | $38 | $27 |
| J0177 | Injection, aflibercept hd, 1 mg | 2,880 | $331 | $263 |
| 92014 | Established patient complete exam of visual system | 2,051 | $117 | $77 |
| 67028 | Injection of drug into eye | 1,457 | $106 | $78 |
| J0178 | Injection, aflibercept, 1 mg | 1,154 | $831 | $659 |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 786 | $85 | $60 |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 492 | $121 | $88 |
| J2778 | Injection, ranibizumab, 0.1 mg | 253 | $159 | $126 |
| J3590 | Unclassified biologics | 61 | $2,661 | $2,113 |
| 92250 | Photography of the retina | 58 | $33 | $25 |
| 92083 | Exam of visual field with extended testing | 55 | $59 | $42 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | MD046551L | PA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Pennsylvania
- NPI 1255328373
- NPI 1821275702
- NPI 1982648226
- NPI 1609876994
- NPI 1255443073
- NPI 1578857389
- NPI 1538113865
- NPI 1275506529
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.